RESUMEN
BACKGROUND: Hepatitis C is a viral infection caused by the hepatitis C virus (HCV) with people who inject drugs as the main group at risk worldwide. AIM: This study investigated the differences in uptake for HCV screening and treatment between persons in opioid substitution therapy (OST) and the other members of the Christian Health Insurance Fund in Belgium. METHODS: Invoice data were retrospectively collected from the Christian Health Insurance Fund, representing 42% of the healthcare users. Information on demographics, screening, diagnostic tests, treatment and disease progression was obtained from 2008 till 2013. All people in this study were aged 20-65 year. Persons in the OST group were identified as having at least one prescription reimbursed for methadone. This group was compared to the other members of the Insurance Fund not on OST (NOST). RESULTS: The Insurance Fund registered 8,409 unique OST and 3,525,190 members in the general group. HCV RNA screening rate was higher in the OST group after correction for age and gender (4.3% vs. 0.2%). Ribavirin reimbursement, did not differ between the OST and NOST group screened for HCV RNA (16.9% vs. 14.4%), though the probability of having ribavirin reimbursed was smaller for females than for males. Procedures concerning disease progression were reimbursed less frequently in the HCV RNA screened OST group compared to the NOST group (0.3% vs. 1.2%). CONCLUSION: People on OST were screened more often for HCV RNA. However, the general uptake for HCV screening and treatment in both populations remained suboptimal.
Asunto(s)
Hepatitis C , Abuso de Sustancias por Vía Intravenosa , Antivirales/uso terapéutico , Bélgica , Femenino , Hepacivirus , Hepatitis C/tratamiento farmacológico , Humanos , Masculino , Tratamiento de Sustitución de Opiáceos , Estudios RetrospectivosRESUMEN
The United States lacks a set of unified electronic waste recycling laws, contributing in part to the observed low rate of e-waste recycling behaviors among consumers. Individual factors of consumers contributing to the low recycling rates are not well understood. The objective of this study was to evaluate consumer behaviors, including barriers, surrounding e-waste recycling at a large Midwestern university in the United States. A survey was administered to faculty, graduate students, undergraduate students, and staff to determine their personal recycling habits, knowledge, and beliefs. The results indicate that free access to disposal, lack of consumer knowledge about products and disposal sites, and access to a recycling facility within a reasonable distance are all important factors in consumer decisions. Policy-makers and waste management professionals should focus on promotion of e-waste recycling behaviors through increased access to free or low-cost recycling as well as through the creation of recycling incentives.
Asunto(s)
Residuos Electrónicos , Eliminación de Residuos , Administración de Residuos , Humanos , Reciclaje , Encuestas y Cuestionarios , UniversidadesRESUMEN
No data have been reported yet on treatment outcome in persons who inject drugs (PWID) infected with hepatitis C virus treated with boceprevir or telaprevir in combination with peginterferon (Peg IFN) and ribavirin (RBV). Additionally, there are concerns about the safety of boceprevir and telaprevir in some subgroups of patients with hepatitis C (HCV). In a cohort of HCV patients infected with genotype 1 in Belgium, treatment outcome of patients infected due to IV drug use was analyzed and compared with patients who have no history of substance use. The study population consisted of 179 patients: 78 PWID and 101 controls treated with boceprevir (n = 79) or telaprevir (n = 100) additional to Peg IFN and RBV; 53 (30%) had advanced disease (F3, F4) and 79 (44%) had an antiviral therapy previously. There were no significant differences in the baseline characteristics between both groups, except that PWID patients were more frequently infected with genotype 1a (67% vs 21%), were younger and were predominantly male. Psychiatric complaints during follow-up occurred more frequently in the PWID patients: 24% versus 11% (P = .02). Treatment failure for other reasons than absence of viral response was 70% and 64% in PWID and non-PWID respectively. The sustained viral response (SVR) rates were similar in both groups (71% in PWID vs 72% in non-PWID); with a non-inferiority test with -5% margin there is a difference of -1% (95% CI [-15%, 13%]) and P = 0.30. There are no reasons to exclude PWID from treatment with boceprevir, telaprevir and novel antiviral therapies.
Asunto(s)
Antivirales/administración & dosificación , Genotipo , Hepacivirus/aislamiento & purificación , Hepatitis C Crónica/tratamiento farmacológico , Oligopéptidos/administración & dosificación , Prolina/análogos & derivados , Abuso de Sustancias por Vía Intravenosa/complicaciones , Adulto , Bélgica , Quimioterapia Combinada/métodos , Femenino , Hepacivirus/clasificación , Hepacivirus/genética , Hepatitis C Crónica/virología , Humanos , Interferón-alfa/administración & dosificación , Masculino , Persona de Mediana Edad , Prolina/administración & dosificación , Estudios Prospectivos , Estudios Retrospectivos , Ribavirina/administración & dosificación , Resultado del TratamientoAsunto(s)
Angiografía de Substracción Digital/métodos , Neoplasias Encefálicas/diagnóstico , Seno Cavernoso/patología , Imagen por Resonancia Magnética/métodos , Paraganglioma/diagnóstico , Adolescente , Neoplasias Encefálicas/cirugía , Seno Cavernoso/cirugía , Medios de Contraste , Diagnóstico Diferencial , Femenino , Humanos , Aumento de la Imagen/métodos , Paraganglioma/cirugíaRESUMEN
BACKGROUND: Nocturnal reflux is important in the pathogenesis of esophagitis. The relationship between reflux and sleep is poorly understood, although data support both paradigms of nocturnal reflux causing arousal and nocturnal arousal allowing reflux. Furthermore, the effect of fundoplication on sleep is unknown. METHODS: Seven volunteers and 11 patients with gastroesophageal reflux disease (GERD) and nocturnal symptoms were studied with esophageal pH and polysomnography at baseline and at 8 to 10 weeks follow-up evaluation, with patients undergoing interval fundoplication. Gastrointestinal and sleep questionnaires were completed before each study. RESULTS: Questionnaire data between the groups showed differences at baseline, which were eliminated by surgery. No objective differences in sleep were observed between the groups at baseline or at follow-up evaluation. However, the patient group significantly increased the fraction of the night spent in deeper sleep (49.6% vs 58.3%; p = 0.022). Reflux events were associated with arousals in sleep. CONCLUSIONS: Fundoplication improves both subjective and objective sleep quality in patients with nocturnal GERD symptoms.
Asunto(s)
Esofagitis Péptica/complicaciones , Reflujo Gastroesofágico/complicaciones , Trastornos del Sueño-Vigilia/complicaciones , Sueño/fisiología , Estudios de Casos y Controles , Ingestión de Alimentos , Electroencefalografía , Esofagitis Péptica/fisiopatología , Esofagitis Péptica/cirugía , Femenino , Fundoplicación , Reflujo Gastroesofágico/fisiopatología , Reflujo Gastroesofágico/cirugía , Humanos , Concentración de Iones de Hidrógeno , Masculino , Persona de Mediana Edad , Trastornos del Sueño-Vigilia/fisiopatología , Factores de TiempoRESUMEN
Hashimoto's encephalopathy is a chronic relapsing and remitting encephalopathy associated with antithyroid antibodies. Seizures are a frequent manifestation, but are not well characterized in the literature with respect to their onset. We describe a 48-year-old patient with recurrent encephalopathy and seizures, and elevated antithyroid antibodies. One seizure was documented with video-EEG monitoring using scalp and sphenoidal electrodes. The ictal discharge originated in the left mesial-basal temporal region. MRI showed an increased T2 signal in the white matter of the centrum semiovale, but no temporal pathology. Symptoms resolved after treatment with prednisone and azathioprine. Hashimoto's encephalopathy should be considered in patients with unexplained encephalopathy and seizures, including those originating in the temporal lobe.